skip to Main Content

Welcome

Celebrating 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Congress and Administration Take Aggressive Action to Address COVID-19 Pandemic but Providers Continue to Struggle

Congress has passed four pieces of legislation and the Centers for Medicare & Medicaid Services…

read more

USP General Chapter News. Media Fill Test Kit

Implementation of the new USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations is still…

read more

HHS Attestation Update

As AMA reported in the AMA Advocacy Update of May 22, HHS announced that providers need to…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

06/26/22: Membership Application Deadline to be eligible for AAOA Member rate for the 2022 Basic Course

07/01/22: Scientific Abstract Submission Deadline
Learn more

07/28/22: Membership Application Deadline to be voted in at the 2022 Annual Meeting

12/01/22: Research Grant Cycle
Learn more

04/01/23: Fellow Exam Application Deadline
Learn more

06/01/23: Research Grant Cycle
Learn more

EDUCATION

Register today for the hybrid 2022 AAOA Basic Course in Allergy & Immunology. The Basic Course in Allergy & Immunology presents basic concepts and techniques applicable to the clinical care of allergic patients. Learn More

RESIDENTS

For information about Resident opportunities, DosedDaily, research grants, and other resources. Learn More

IFAR

Available Now

aaoaf-ifar

IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2022 AAOA Basic Course - Hybrid!
The Diplomat Beach Resort, Hollywood, FL
June 1, 2022 - Pre-Work On-Demand
June 30-July 2, 2022 - F2F - Live Stream
Learn More and Register
On-Demand and Live Stream Access

2022 AAOA Annual Meeting
Loews Philadelphia, PA
September 9-11, 2022- F2F - Live Stream
Learn More and Register

2023 AAOA Advanced Course in Allergy & Immunology
March 30 - April 1, 2023
The Hythe Vail
Formerly the Vail Marriott Mountain Resort

USP 797 Online Module
Learn More and Register

News and Updates

CRS with/without Nasal Polyps Podcast Series: Common Co-morbidities

In the second episode of CRS with/without Nasal Polyps Podcast Series: Common Co-morbidities, Jennifer Villwock,…

read more

CRS with/without Nasal Polyps Podcast Series: From Immune Pathways to Clinical Practice

In the first episode of CRS with/without Nasal Polyps Podcast Series: From Immune Pathways to Clinical…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

Allergy to Cannabis

James Connolly, MD;  Alfred Sassler, MD – AAOA PPR Committee

The past few years have seen increasing legalization of both medical and recreational marijuana across the United States. Concurrently, there has also been burgeoning use of cannabis-derived products such as hemp in the textile industry to produce fiber, yarn, and rope and hempseed for protein rich supplement therapy. As a result, many of us are seeing, or at least fielding questions about, marijuana allergy.

In 1996, the state of California legalized medical marijuana leading to many other states following suite. Now there are 36 states with access to medical marijuana. In 2012, the states of Colorado and Washington legalized recreational marijuana leading to many other states following their lead to presently 17 total states. Currently, only 3 states have no public cannabis access programs (Kansas, Nebraska, and Idaho). From a regulatory perspective, marijuana remains a Schedule 1 substance by federal law. However, United States Department of Justice is currently respecting the autonomy of each state the establish state-based enforcement efforts should the state legalize marijuana. There is also an increasing market for CBD oil to treat muscle and joint pain, as well as many other medical issues. With the increasing availability, the risk of allergies due to both accidental and prescribed exposures is also on the rise. Physicians treating allergy must keep in mind that their patients could be exposed to this antigen.

 LegalizedStates & Territories
Medical Marijuana36 statesAlaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Hawaii, Illinois, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, New Hampshire, New Jersey, New Mexico, New York, Nevada, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Dakota, Utah, Vermont, Virginia, Washington, West Virginia  
Recreational Marijuana18 statesAlaska, Arizona, California, Colorado, Connecticut, Illinois, Maine, Massachusetts, Michigan, Montana, Nevada, New Jersey, New Mexico, New York, Oregon, Vermont, Virginia, Washington and Washington, DC.

Cannabis sativa (marijuana/hemp) is an annual, dioecious, and anemophilous flowering plant that belongs to the Cannabaceae family and native to Central and South Asia but thrives in the southwest US. It pollenates during late summer to early fall. Its pollen is typically 23-28 mu in diameter, very buoyant allowing for wind distribution miles away from the male plant. Cannabis sensitization can occur from inhalation, smoking, touching, or ingestion marijuana, hemp, or cannabis products like CBD, CBN, and THC. Cannabis allergy can cause the usual allergic rhinitis, allergic conjunctiva, and asthma symptoms, but can occasionally cause anaphylaxis. This has been noted mostly in hempseed oral exposure. It has also been seen to have cross-reactivity with cypress tree and certain foods, like tomato, hazelnut, peach, apple, and gold kiwi.

Currently, cannabis allergy diagnosis relies heavily on history.  Confirmation testing can only be done by non-standardized technique of skin prick testing, using clinic made extract from leaves, buds, and flowers with seeds crushed and blended. Because extraction techniques and source material can vary between extract preparation each time, a standardized mass-produced extract is needed to improve accuracy. In vitro testing also has limitation because it requires assistance from research laboratories and currently the only federally approved Cannabis sources in the United States is located at the University of Mississippi.

Difficulty in creating a mass-produced extract or in vitro test arises from multiple potential cannabis major antigens: Delta-9-tetrahydrocannabinol (THC), nonspecific lipid transfer protein (Can s 3), Thaumatin-like protein, Riblose-1,5-biphosphonate carboxylase/oxygenase (RuBisCO), and/or Oxygen-evolving enhancer protein 2. Also, there are multiple potential cannabis minor antigens: profilins (panallergen), poly-galacturonase, adenosine triphosphate synthase (bovine), phosphoglycerate kinase (candida), glyceralderhyde-3-phosphate dehydrogenase kinase (wheat, fungi, and rambutan), luminal binding protein in root (hazel pollen and fungi), and carbohydrate determinants.

Treatment should be avoidance, since at this time there is no standardized extract to provide a reasonable safe way to offer desensitization with immunotherapy. Additionally, routine allergic rhinitis medications can be used for symptom relief, like topical and systemic steroids, topical and systemic antihistamines, and anti-leukotrienes.

Back To Top